FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
vvasiliigton,	D.C.	20043

STATEMENT	OF CHANG	ES IN BENEFI	ICIAL OWNERS	HIP

OMB APPROVAL								
OMB Number: 3235-0287								
Estimated average burden								
hours per response.	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1 Name ar	nd Address of	Reporting Person*			2.	Issue	Nam	e and Tid	ker or	Tradino	Symbol		15	. Rela	tionship o	f Reporting	a Pers	on(s) to Issu	ier
1. Name and Address of Reporting Person* Morrison Briggs				2. Issuer Name and Ticker or Trading Symbol Syndax Pharmaceuticals Inc [SNDX]								Check	all applica	plicable)					
17101115	<u> </u>	<u>. </u>			_									X	Director			10% Ow	
(Last)	(F	irst)	(Middle)		3	3. Date of Earliest Transaction (Month/Day/Year)							-	X	Officer (below)	give title		Other (s below)	pecify
` '	,	RMACEUTICA	,	C		09/19/2022				Saction (Month/Day/Tear)					Pre	resident, Head of R&D		of R&D	
		RIVE, BUILDII																	
33 GAI1	inoose D	KIVE, BUILDII	NO D, I	LOOK 3	_	4. If Amendment, Date of Original Filed (Month/Day/Year)						- 6	6. Individual or Joint/Group Filing (Check App					licable	
(Street)					_ 4.	II AIII	SHUITIE	ent, Date	oi Origi	IIIai File	eu (Montin/Da	iy/ rear)		ine)	idual of Jo	Jiill/Group	rilling	(Crieck App	licable
WALTH.	AM M	ΙA	02451											X	Form fil	ed by One	Repo	rting Persor	۱
					_										Form filed by More than One Reporting Person				
(City)	(S	tate)	(Zip)												reison				
		Ta	hla I - N	Non-Der	rivativ	/o S	CUr	itias A	nuire	od D	isposed o	of or Bo	neficia	ally ()wned				
4 700 . 64	2		DIC 1 - 1			_			_	-u, D	-	•		ally (
Di			2. Transa Date (Month/D		Execution Date,		n Date,	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and Amount (A) or (D) Price			5)	Securitie Beneficia	5. Amount of Securities Beneficially Dwned Following		n: Direct I r Indirect I	7. Nature of Indirect Beneficial Ownership	
								Code	v			Price		Reported Transaction(s) (Instr. 3 and 4)				Instr. 4)	
Common	Stock		09/19/2		/2022)22		M	П	114,339	A	\$10	10.9 1		2,175		D		
Common	Stock			09/19/202		22		S ⁽¹⁾	П	114,339	D	\$23.02	84 ⁽²⁾ 17.		.836		D		
Common	Stock			09/20/	/2022	22		M		59,649	A	\$10		77	,485		D		
Common Stock 09/20/20					/2022				S ⁽¹⁾		59,649	D	\$23.25	29(3)	17,	836		D	
			Table I								posed of, , converti				wned				
					, puts	, cai	_		_			1		_					1
1. Title of Derivative Security (Instr. 3)	erivative Conversion Date Execution Date, curity or Exercise (Month/Day/Year) if any			l. Fransaction Code (Instr. S)				6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8	. Price of Perivative Security Instr. 5)	9. Numbe derivative Securities Beneficial Owned Following Reported Transaction	e es ally g	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
													Amoun	ıt		(Instr. 4)	-1(0)		
					Code	v	(A)	(D)	Date Exerc	isable	Expiration Date	Title	Numbe of Shar						
Stock Options (Right to buy)	\$10.9	09/19/2022			М			114,339	(4	4)	09/09/2025	Common Stock	114,3	39	\$0.00	0.00		D	
Stock Options (Right to buy)	\$10.9	09/20/2022			M			59,649	(4	4)	09/09/2025	Common Stock	59,64	19	\$0.00	0.00		D	

Explanation of Responses:

- 1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 774,958 options to purchase shares of common stock that are vested and immediately exercisable and a total of 370,042 options to purchase shares of common stock that have not yet vested.
- 2. The sale prices ranged from \$22.50 to \$23.35
- 3. The sale prices ranged from \$22.60 to \$23.75
- 4. This option is fully vested.

Remarks:

/s/ Michael A. Metzger, 09/21/2022 Attorney-in-fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.